Background
==========

Despite tremendous advances in the prevention and treatment of coronary artery disease (CAD), diagnosis and prognosis remain difficult issues. The measurement of coronary calcium deposits has been proposed as a new non-invasive diagnostic tool. Calcium deposition can be quantified non-invasively at a very early stage by electron beam computed tomography (EBCT) using the Agatston method \[[@B1]\]. EBCT scanners are not as versatile as multidetector slice computed tomography (MDCT), but their technological simplicity without moving parts permits more rapid examinations at lower costs \[[@B2]\]. While MDCT is also widely used for the assessment of coronary calcium, the current article focuses on evaluating EBCT. A more detailed examination of EBCT versus MDCT technology appears in a recent scientific statement from the American Heart Association \[[@B2]\].

While the measurement of coronary calcification using EBCT has emerged as a promising screening and diagnostic tool for CAD, there is concern about widespread dissemination of this technology into routine clinical practice before adequate evaluation. Herein we provide a systematic review of the literature on the efficacy of EBCT with separate analyses for both asymptomatic and symptomatic patients. We improve upon previous meta-analyses by: (1) updating previous conclusions with results of recent articles; (2)providing quantitative support for guidelines defining low, moderate and high EBCT scores \[[@B3]\] for both asymptomatic and symptomatic patients; and (3) providing risk ratios for comparing both positive and negative predictive values between low, moderate and high EBCT score categories.

Methods
=======

Data sources and searches
-------------------------

We searched the following electronic literature databases: PUBMED, MEDLINE, EMBASE, Current Contents, INAHTA and Cochrane Collaboration. Search terms were \'electron beam tomography\' OR \'electron beam\' OR \'EBT\' OR \'EBCT\' OR \'ultrafast\' AND \'coronary artery disease\' OR \'coronary blood vessel\' OR \'coronary\' AND \'calcification\' OR \'calcium\'. Bibliographies of identified articles were searched further. We included studies that were published before 31 July 2006.

Study selection, data extraction and quality assessment
-------------------------------------------------------

We required that studies: (1) were published in English; (2) recruited consecutive patients; (3) followed a prospective design for studies of asymptomatic patients; and (4)were designed such that both EBCT and coronary angiography were carried out within 3 months in studies of symptomatic patients. From each study we extracted details of the method of recruitment, inclusion/exclusion criteria, length of follow-up and percentage of completed follow-up (for prospective studies), details of the EBCT protocol, EBCT categories, distribution of patients across EBCT categories, outcome definition, percentage of patients with the outcome of interest in each EBCT category and aggregate results on covariates such as age, sex, smoking, diabetes, hypertension, hypercholesterolemia and history of CAD. Data were extracted by two of the authors (KC and ND). Relevant items from the Standards for Reporting of Diagnostic Accuracy (STARD) guidelines were used to evaluate the quality of individual articles \[[@B4]\].

Data synthesis and analysis
---------------------------

### Defining categories on the EBCT scale

There are no standardized EBCT cut-offs, which makes comparative analyses difficult. One guideline \[[@B3]\] has suggested the following cut-offs: 0 (very low), 1--10 (low), 11--100 (moderate), 101--400 (moderately high), \>400 (high). For each selected study, we elected to transform the reported categories as closely as possible into one of three standardized categories: low (0--10), moderate (11--400) and high (\>400). The lowest and highest categories in a given study were always classified as low and high, respectively. When there was uncertainty about the EBCT classification we carried out sensitivity analyses by placing the category into the adjacent group.

### Hierarchical meta-analysis comparing predictive values between EBCT categories

For each category we calculated the probability of the outcome (positive predictive value) and the probability of the absence of the outcome (negative predictive value). Given the variability in predictive values across studies, we decided that only the ratios comparing predictive values between categories could reasonably be pooled across studies. This was done by means of a hierarchical meta-analysis \[[@B5]\]. A separate model was fit for each pair of categories that were compared. We chose to compare categories using risk ratios, rather than the commonly used odds ratio, for greater interpretability \[[@B5]\]. Non-informative prior distributions were used for all parameters, thus the results reflect the information in the observed data. We reported the posterior median and 95% credible intervals for the parameters of interest. The models were implemented using WinBUGS software. A copy of the program is available from the first author upon request.

Results
=======

The results of the literature search are summarized in Figure [1](#F1){ref-type="fig"}. From 745 initial studies, we identified 9 prospective studies of asymptomatic patients \[[@B6]-[@B14]\] and 10 cross-sectional studies of symptomatic patients \[[@B15]-[@B24]\].

![Flowchart summarizing study selection.](1741-7015-5-35-1){#F1}

Quality of individual studies
-----------------------------

Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} summarize the quality of each study according to relevant criteria from the STARD guidelines \[[@B4]\]. Most studies of asymptomatic patients excluded patients with a history of heart disease or with a suspected myocardial infarction (MI). However, there was variability in the source population: in some studies patients were self-referred, while in others they were referred by a physician or identified during a routine annual examination. These studies reported the risk of hard outcomes (unstable angina, MI, stroke, coronary death, all-cause mortality) and sometimes also included the softer cardiac outcome of coronary revascularization (Table [3](#T3){ref-type="table"}) \[[@B14],[@B11]\]. Most studies of symptomatic patients recruited patients with MI or suspected MI, who would normally be considered candidates for angiography. All of these studies defined coronary disease as the presence of at least 50% coronary stenosis based on angiographic findings. A summary of the demographic and clinical characteristics from the selected studies is given in Table [4](#T4){ref-type="table"}. There was no clear difference in the distribution of age, sex, smoking and history of CAD among studies of asymptomatic and symptomatic patients based on the reported aggregate data. The percentage of patients with hypertension and diabetes was somewhat higher in studies of symptomatic patients compared with asymptomatic patients.

###### 

Quality of studies of asymptomatic subjects

  **Item**                                    **Value**                                                      **Wong *et al*. \[6\]**   **Arad *et al*. \[11\]**   **Raggi *et al*. \[7\]**   **Kondos *et al*. \[8\]**   **Shaw *et al*. \[9\]**   **Greenland *et al*. \[10\]**   **Taylor *et al*. \[12\]**   **Vliegenthart *et al*. \[13\]**   **LaMonte *et al*. \[14\]**
  ------------------------------------------- -------------------------------------------------------------- ------------------------- -------------------------- -------------------------- --------------------------- ------------------------- ------------------------------- ---------------------------- ---------------------------------- -----------------------------
  Patient recruitment                         1: Self referred                                               2                         NR                         2                          1                           2                         1                               3                            3                                  2
                                              2: Clinician referred                                                                                                                                                                                                                                                                                
                                              3: Population sample                                                                                                                                                                                                                                                                                 
  Exclusion criteria                          1: Did not exclude history of heart disease                    2                         2                          NR                         2                           2                         2                               2                            2                                  2
                                              2: Excluded history of heart disease                                                                                                                                                                                                                                                                 
  Outcome defined                             1: All cause mortality                                         2                         2                          3                          3                           1                         3                               3                            2                                  2
                                              2: Coronary outcomes\* and revascularization                                                                                                                                                                                                                                                         
                                              3: Coronary outcomes\* only                                                                                                                                                                                                                                                                          
  EBCT categories                             1: Quartiles or pre-selected cut-offs                          1                         1                          2                          1                           1                         1                               1                            1                                  1
                                              2: Age -- sex adjusted                                                                                                                                                                                                                                                                               
  Outcome extraction blinded to EBCT score    1: No                                                          2                         2                          2                          2                           2                         2                               2                            2                                  2
                                              2: Yes                                                                                                                                                                                                                                                                                               
  Demographic characteristics, risk factors   NR: Not reported                                               1                         1                          1                          1                           1                         1                               1                            1                                  1
                                              1: Reported (see Table 3)                                                                                                                                                                                                                                                                            
  Percentage follow-up                        NR: Not reported                                               NR                        1                          1                          1                           1                         1                               1                            1                                  1
                                              1: Yes (see Table 4)                                                                                                                                                                                                                                                                                 
  Adjusted results available                  1: Yes but cannot be used in meta-analysis                     1                         1                          3                          2                           3                         3                               2                            3                                  3
                                              2: Yes at single cut-off and can be used in meta-analysis.                                                                                                                                                                                                                                           
                                              3: Yes at multiple cut-offs and can be used in meta-analysis                                                                                                                                                                                                                                         
  Total                                       Maximum: 17                                                    11                        11                         14                         13                          13                        14                              15                           15                                 14

\*Coronary outcomes: angina, myocardial infarction, coronary death.

###### 

Quality of studies of symptomatic subjects

  **Item**                                    **Value**                                                      **Budoff *et al*. \[15\]**   **Baumgart *et al*. \[16\]**   **Seese *et al*. \[17\]**   **Yao *et al*. \[18\]**   **Chen *et al*. \[19\]**   **Bielak *et al*. \[20\]**   **Hosoi *et al*. \[21\]**   **Budoff *et al*. \[22\]**   **Almeda *et al*. \[23\]**   **Knez *et al*. \[24\]**
  ------------------------------------------- -------------------------------------------------------------- ---------------------------- ------------------------------ --------------------------- ------------------------- -------------------------- ---------------------------- --------------------------- ---------------------------- ---------------------------- --------------------------
  Patient recruitment                         NR: Not reported                                               1                            1                              1                           1                         1                          1                            1                           1                            NR                           1
                                              1: Undergoing CAG for clinical indications                                                                                                                                                                                                                                                                                     
  Exclusion criteria                          NR: Not reported                                               NR                           1                              NR                          NR                        1                          1                            NR                          1                            NR                           NR
                                              1: History of CAD/revascularization                                                                                                                                                                                                                                                                                            
  Outcome defined                             1: No                                                          2                            2                              2                           2                         2                          2                            2                           2                            2                            2
                                              2: Yes                                                                                                                                                                                                                                                                                                                         
  EBCT categories                             1: Quartiles or pre-selected cut-offs                          1                            1                              1                           1                         1                          1                            1                           1                            1                            1
                                              2: Age -- sex adjusted                                                                                                                                                                                                                                                                                                         
  Outcome measurement blinded to EBCT score   1: No                                                          NR                           2                              NR                          NR                        2                          NR                           2                           2                            NR                           2
                                              2: Yes                                                                                                                                                                                                                                                                                                                         
  Demographic characteristics                 NR: Not reported                                               1                            1                              1                           NR                        1                          1                            1                           1                            1                            1
                                              1: Reported                                                                                                                                                                                                                                                                                                                    
  Risk factors                                NR : Not reported                                              NR                           NR                             NR                          NR                        1                          1                            1                           NR                           1                            1
                                              1: Reported (see Table 3)                                                                                                                                                                                                                                                                                                      
  Adjusted results available                  1: Yes but cannot be used in meta-analysis                     1                            NR                             NR                          NR                        2                          3                            1                           2                            2                            NR
                                              2: Yes at single cut-off and can be used in meta-analysis.                                                                                                                                                                                                                                                                     
                                              3: Yes at multiple cut-offs and can be used in meta-analysis                                                                                                                                                                                                                                                                   
  Total                                       Maximum: 13                                                    6                            8                              5                           4                         11                         10                           9                           10                           7                            8

###### 

Definition of outcomes and length of follow-up in studies of asymptomatic subjects

  **Study**                          **Definition of outcome\***                                              **Mean length of follow-up (years)**   **Follow-up completed (%)**
  ---------------------------------- ------------------------------------------------------------------------ -------------------------------------- -----------------------------
  1\. Wong *et al*. \[6\]            MI, stroke, revascularization                                            3.3                                    \-\--
  2\. Raggi *et al*. \[7\]           MI, sudden cardiac death or death due to MI                              2.7                                    100%
  3\. Kondos *et al*. \[8\]          Death (owing to CHD or unknown cause), MI                                3.1                                    64%
  4\. Shaw *et al*. \[9\]            All-cause mortality                                                      5                                      100%
  5\. Greenland *et al*. \[10\]      MI or CHD death                                                          7.0                                    87.5%
  6\. Arad *et al*. \[11\]           Coronary death, non-fatal MI, CABG, PTCA                                 4.3                                    94%
  7\. Taylor *et al*. \[12\]         Sudden cardiac death, MI, unstable angina                                3.0                                    99.2%
  8\. Vliegenthart *et al*. \[13\]   Incident MI, CHD mortality, revascularization                            3.3                                    \~100%
  9\. LaMonte *et al*. \[14\]        Non-fatal MI or death from coronary causes, coronary revascularization   3.5                                    70%

\*CABG, coronary artery bypass graft; CHD, coronary heart disease; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty.

###### 

Summary of demographic characteristics and risk factors

  **Study**                              **Age mean (SD) (years)**   **Male (%)**   **Smokers (%)**   **Hypertension (%)**   **Diabetes (%)**   **History of CAD\* (%)**
  -------------------------------------- --------------------------- -------------- ----------------- ---------------------- ------------------ --------------------------
  **Studies of asymptomatic subjects**                                                                                                          
                                                                                                                                                
  1\. Wong *et al*. \[6\]                64 (\--)                    76             24                26                     5                  \-\--
  2\. Raggi *et al*. \[7\]               52 (9)                      50             65                52                     15                 47
  3\. Kondos *et al*. \[8\]              51 (9)                      74             48                20                     3                  \-\--
  4\. Shaw *et al*. \[9\]                53 (0.1)                    60             40                44                     9                  69
  5\. Greenland *et al*. \[10\]          66 (8)                      90             18                41                     \-                 \-\--
  6\. Arad *et al*. \[11\]               53 (11)                     71             10                34                     6                  21
  7\. Taylor *et al*. \[12\]             43 (3)                      82             8                 29                     1                  32
  8\. Vliegenthart *et al*. \[13\]       71 (6)                      43             16                60                     12                 19
  9\. LaMonte *et al*. \[14\]            54 (10)                     64             9                 18                     3                  \-\--
                                                                                                                                                
  **Studies of symptomatic subjects**                                                                                                           
                                                                                                                                                
  1\. Budoff *et al*. \[15\]             56 (12)                     64             \-\--             \-\--                  \-\--              \-\--
  2\. Baumgart *et al*. \[16\]           54 (9)                      79             \-\--             \-\--                  \-\--              \-\--
  3\. Seese *et al*. \[17\]              55 (8)                      87             \-\--             \-\--                  \-\--              \-\--
  4\. Yao *et al*. \[18\]                \-\--                       \-\--          \-\--             \-\--                  \-\--              \-\--
  5\. Chen *et al*. \[19\]               66 (10)                     85             53                59                     16                 32
  6\. Bielak *et al*. \[20\]             56 (11)                     76             62                45                     13                 51
  7\. Hosoi *et al*. \[21\]              63 (-)                      67             \-\--             56                     36                 \-\--
  8\. Budoff *et al*. \[22\]             58 (11)                     63             \-\--             \-\--                  \-\--              \-\--
  9\. Almeda *et al*. \[23\]             60                          78             14                51                     18                 57
  10\. Knez *et al*. \[24\]              62 (10)                     78             23                66                     22                 \-\--

\*CAD, coronary artery disease.

EBCT protocol
-------------

Eighteen studies followed the Agatston method for scoring; only one study followed the Erlanger method for scoring \[[@B17]\]. While all studies used a threshold of greater than 130 Hounsfield units to identify a calcified lesion, there was wide variability in the minimum area in which the signal had to be observed ranging from 0.44 to 1.02 mm^2^. The width of each slice was 3 mm in all studies except one, which used 6 mm slices\[[@B10]\]. The scan time per rotation was 100 ms in all studies. The percentage of the R-R interval to which the scan acquisition trigger was set was typically 80%.

Results from prospective studies of asymptomatic patients
---------------------------------------------------------

### Distribution of EBCT categories and risk of outcome

The distributions of EBCT scores as reported in each study are given in Table [5](#T5){ref-type="table"} along with the summary categorization from low to high. The cut-offs reported by individual studies varied greatly, although most studies reported the number of patients with a calcium score of zero. The probability of the outcome increased with increasing EBCT score in all studies (Figure [2](#F2){ref-type="fig"} and Table [5](#T5){ref-type="table"}). Given the considerable variation between studies in the risk of developing CAD (see Table [5](#T5){ref-type="table"}), we concluded that it was not clinically meaningful to pool predictive values across studies. We concentrated instead on pooling the ratios of moderate- or high-risk categories to the baseline low category from each study.

###### 

EBCT score distribution and positive predicted values in studies of asymptomatic patients

                                     **Reported classification**      **Simplified classification**                                                                                  
  ---------------------------------- -------------------------------- ------------------------------- ----------------------------- ------------------- ---------------------------- -----------------------------
  **Study**                          **EBCT category**                **Number (%) of patients**      **Number (%) with outcome**   **EBCT Category**   **Number (%) of patients**   **Number (%) with outcome**
                                                                                                                                                                                     
  1\. Wong *et al*. \[6\]            0                                398 (42.9)                      4 (1.0)                       Low                                              
                                     1--15                            133 (14.3)                      1 (0.8)                       Low                 531 (57.2)                   5 (0.1)
                                     16--80                           134 (14.4)                      5 (3.7)                       Moderate                                         
                                     81--270                          131 (14.1)                      7 (5.3)                       Moderate            265 (28.6)                   12 (4.5)
                                     ≥271                             132 (14.2)                      11 (8.3)                      High                132 (14.2)                   11 (8.3)
                                     *Total*                          *928*                           *28*                                                                           
  2\. Raggi *et al*. \[7\]           0                                292 (46.2)                      1 (0.3)                       Low                 292 (46.2)                   1 (0.3)
                                     1--99                            219 (34.7)                      12 (5.5)                      Moderate                                         
                                     100--400                         74 (11.7)                       8 (10.8)                      Moderate            293 (46.3)                   20 (6.8)
                                     \>400                            47 (7.4)                        6 (12.8)                      High                47 (7.4)                     6 (7.4)
                                     *Total*                          *632*                           *27*                                                                           
  3\. Kondos *et al*. \[8\]          0                                1816 (32.2)                     5 (0.3)                       Low                 1816 (32.2)                  5 (0.3)
                                     \>0                              3819 (67.8)                     53 (1.4)                      Moderate/high       3819 (67.8)                  53 (1.4)
                                     *Total*                          *5635*                          *58*                                                                           
  4\. Shaw *et al*. \[9\]            ≤10                              5946 (57.3)                     62 (1.0)                      Low                 5946 (57.3)                  62 (1.0)
                                     11--100                          2044 (19.7)                     53 (3.0)                      Moderate                                         
                                     101--400                         1432 (13.8)                     54 (3.8)                      Moderate            3476 (33.5)                  107 (2.9)
                                     401--1000                        623 (6.0)                       39 (6.3)                      High                                             
                                     \>1000                           332 (3.2)                       41 (12.4)                     High                955 (9.2)                    80 (8.4)
                                     *Total*                          *10377*                         *249*                                                                          
  5\. Greenland *et al*. \[10\]      0                                316 (30.7)                      14 (4.4)                      Low                 316 (30.7)                   14 (4.4)
                                     1--100                           321 (31.2)                      21 (6.5)                      Moderate                                         
                                     101--300                         171 (16.6)                      15 (8.8)                      Moderate            492 (47.8)                   36 (7.3)
                                     ≥301                             221 (21.5)                      34 (15.4)                     High                221 (21.5)                   34 (15.4)
                                     *Total*                          *1029*                          *84*                                                                           
  6\. Arad *et al*. \[11\]           0                                1504 (25)                       8 (0.5)                       Low                 1504 (25.0)                  8 (0.5)
                                     1--99                            1973 (25)                       20 (1)                        Moderate                                         
                                     100--399                         686 (25)                        38 (5.5)                      Moderate            2659 (50.0)                  58 (2.2)
                                     ≥400                             450 (25)                        63 (14)                       High                450 (25.0)                   63 (14.0)
                                     *Total*                          *4613*                          *129*                                                                          
  7\. Taylor *et al*. \[12\]         0                                1261 (77.6)                     7 (0.6)                       Low                 1381 (85.0)                  7 (0.6)
                                     1--9                             120 (7.4)                       0 (0.0)                       Moderate                                         
                                     10--44                           120 (7.4)                       2 (1.7)                       Moderate            120 (7.4)                    2 (1.7)
                                     \>44                             124 (7.6)                       5 (4.0)                       Moderate/high       124 (7.6)                    5 (4.0)
                                     *Total*                          *1625*                          *14*                                                                           
  8\. Vliegenthart *et al*. \[13\]   0--100                           905 (50.4)                      7 (0.8)                       Low                 905 (50.4)                   7 (0.8)
                                     101--400                         425 (23.7)                      13 (3.1)                      Moderate            425 (23.7)                   13 (3.1)
                                     401--1000                        269 (15.0)                      13 (4.5)                      High                                             
                                     \>1000                           196 (10.9)                      17 (8.7)                      High                365 (25.9)                   30 (8.2)
                                     *Total*                          *1795*                          *50*                                                                           
  9\. LaMonte *et al*. \[14\]        0                                5472 (50.9)                     15 (0.3)                      Low                 5472 (50.9)                  15 (0.3)
                                     1--38 (Men), 1--16 (Women)       1760 (16.4)                     19 (1.1)                      Moderate                                         
                                     39--249 (Men), 17--112 (Women)   1758 (16.4)                     62 (3.5)                      Moderate            3518 (32.8)                  81 (2.3)
                                     ≥250(Men), ≥113 (Women)          1756 (16.3)                     191 (10.9)                    High                1756 (16.3)                  191 (10.9)
                                     *Total*                          *10746*                         *287*                                                                          

\*CAD, coronary artery disease.

![Distribution of positive predictive values across EBCT score categories.](1741-7015-5-35-2){#F2}

### Meta-analysis

A forest plot of the individual and overall risk ratios is given in Figure [3](#F3){ref-type="fig"}. The pooled risk ratios comparing positive predictive values across EBCT categories were statistically significant. A forest plot of the risk ratios of the negative predicted values is given in Figure [4](#F4){ref-type="fig"}. The overall risk ratios comparing the three categories were all close to 1, indicating that despite the fact that the negative predictive values were high the EBCT categorization was not very useful for identifying patients unlikely to have CAD.

![Forest plots from meta-analyses of ratios of positive predictive values among asymptomatic subjects.](1741-7015-5-35-3){#F3}

![Forest plots from meta-analyses of ratios of negative predictive values among asymptomatic subjects.](1741-7015-5-35-4){#F4}

Results from cross-sectional studies of symptomatic patients
------------------------------------------------------------

### Distribution of EBCT categories and risk of outcome

The distribution of EBCT scores in each study is given in Table [6](#T6){ref-type="table"} along with the summary categorization from low to high. As in the case of studies of asymptomatic patients, there was variation in the reported cut-offs, the distribution of EBCT scores and the risk of CAD in each EBCT category. The negative predictive value (probability of no CAD) corresponding to a calcium score of zero ranged from 0.58 to 0.92 in the individual studies.

###### 

EBCT score distribution and positive predictive values in studies of symptomatic subjects

                             **Reported classification**   **Simplified classification**                                               
  -------------------------- ----------------------------- ------------------------------- ------------- --------------- ------------- -------------
  Budoff *et al*. \[15\]     0                             147 (20.7)                      23 (15.6)     Low             147 (20.7)    23 (15.6)
                             \>0                           563 (79.3)                      404 (71.8)    Moderate/high   563 (79.3)    404 (71.8)
                             *Total*                       *710*                           *427*                                       
  Baumgart *et al*. \[16\]   0                             32 (56.1)                       10 (31.3)     Low             32 (56.1)     10 (31.3)
                             \>0                           25 (43.9)                       19 (76.0)     Moderate/high   25 (43.9)     19 (76.0)
                             *Total*                       *57*                            *29*                                        
  Seese *et al*. \[17\]      0                             22 (20.6)                       4 (18.2)      Low             22 (20.6)     4 (18.2)
                             \>0                           85 (79.4)                       83 (97.7)     Moderate/high   85 (79.4)     83 (97.7)
                             *Total*                       *107*                           *87*                                        
  Yao *et al*. \[18\]        0                             26 (40.1)                       11 (42.3)     Low             26 (40.1)     11 (42.3)
                             \>0                           38 (59.9)                       34 (89.5)     Moderate/high   38 (59.9)     34 (89.5)
                             *Total*                       *64*                            *45*                                        
  Bielak *et al*. \[20\]     0                             40 (18.8)                       1 (2.5)       Low                           
                             1--9                          31 (14.6)                       8 (25.8)      Low             71 (33.3)     9 (12.7)
                             10--49                        25 (11.7)                       6 (24.0)      Moderate                      
                             50--99                        13 (6.1)                        7 (53.8)      Moderate                      
                             100--199                      24 (11.3)                       17 (70.8)     Moderate                      
                             200--499                      25 (11.7)                       21 (84.0)     Moderate?       87 (40.8)     51 (58.6)
                             ≥500                          55 (25.8)                       52 (94.5)     High            55 (25.8)     52 (94.5)
                             *Total*                       *213*                           *112*                                       
  Chen *et al*. \[19\]       0--5                          22 (19.0)                       2 (9.1)       Low             22 (19.0)     2 (9.1)
                             6--75                         17 (14.7)                       3 (17.7)      Moderate                      
                             76--500                       29 (15.0)                       24 (82.8)     Moderate?       46 (29.7)     27 (58.7)
                             \>500                         48 (41.4)                       45 (93.8)     High            48 (41.4)     45 (93.8)
                             *Total*                       *116*                           *74*                                        
  Hosoi *et al*. \[21\]      0                             36 (12.8)                       7 (19.4)      Low             74 (26.3)     29 (39.2)
                             1--10                         38 (13.5)                       22 (57.9)     Low                           
                             11--100                       59 (20.9)                       39 (66.1)     Moderate                      
                             101--399                      53 (18.8)                       41 (77.4)     Moderate        112 (39.7)    80 (71.4)
                             \>399                         96 (34)                         93 (96.9)     High            96 (34)       93 (96.9)
                             *Total*                       *282*                           *202*                                       
  Budoff *et al*. \[22\]     0                             386 (20.9)                      39 (10.1)     Low             386 (20.9)    39 (10.1)
                             1--20                         216 (11.7)                      60 (27.8)     Moderate?                     
                             21--80                        230 (12.4)                      108 (47.0)    Moderate                      
                             81--100                       55 (3.0)                        29 (52.7)     Moderate        501 (27.1)    197 (39.3)
                             \>100                         964 (52.1)                      747 (77.5)    High            964 (52.1)    747 (77.5)
                             *Total*                       *1851*                          *983*                                       
  Almeda *et al*. \[23\]     0                             26 (10.6)                       2 (7.7)       Low             26 (10.6)     2 (7.7)
                             \<100                         28 (11.4)                       14 (50.0)     Moderate                      
                             100--399                      71 (28.9)                       39 (54.9)     Moderate        99 (40.3)     53 (53.5)
                             ≥400                          121 (49.2)                      105 (86.8)    High            121 (49.2)    105 (86.8)
                             *Total*                       *246*                           *160*                                       
  Knez *et al*. \[24\]       0                             254 (12.0)                      13 (5.1)      Low                           
                             1--9                          427 (20.2)                      75 (17.6)     Low             681 (32.2)    88 (12.9)
                             10--99                        211 (10.0)                      150 (71.1)    Moderate        211 (10.0)    150 (71.1)
                             \>99                          1223 (57.8)                     1017 (83.2)   High            1223 (57.8)   1017 (83.2)
                             *Total*                       *2115*                          *1255*                                      

\*CAD, coronary artery disease; EBCT, electron beam computed tomography.

\*\*Here \'?\' denotes that the simplified EBCT category could be the adjacent category.

### Meta-analysis

The results of the meta-analyses are presented in Figures [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}. Once again there was a statistically significant difference in the positive predictive values in the low category compared with the other two categories. In particular, the pooled risk ratios suggest that a symptomatic subject with a low score has approximately one-quarter of the risk of having significant angiographic coronary stenosis than the moderate/high categories. This would mean that if the average patient in the moderate/high category had an 80% risk of CAD, the average patient in the low category would have a 20% risk of CAD. The overall risk ratios comparing negative predictive values were significantly different from 1. In particular, negative predictive values in the low category were much higher than in the other two categories suggesting that a symptomatic subject with a low score has a very small likelihood of having coronary stenosis. For three studies \[[@B19],[@B22]\] there was ambiguity in determining the simplified classification of the EBCT score category. However, repeating the meta-analysis following a reclassification of these categories did not affect our final results.
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Discussion
==========

We have carried out a systematic review and meta-analysis of the published literature on the screening and diagnosis of CAD using EBCT. We identified two different types of studies: (1) 9 prospective studies of asymptomatic patients evaluating the predictive validity of EBCT for a mixture of hard outcomes (unstable angina, MI, stroke, coronary death, all-cause mortality) and revascularization; and (2) 10 cross-sectional studies of symptomatic patients evaluating the concurrent validity of EBCT for coronary stenosis as measured by coronary angiography. The risk of coronary events or angiographically confirmed CAD increased consistently with increasing EBCT scores in both types of studies.

Our results provide quantitative support for the cut-offs proposed by Rumberger *et al*. \[[@B3]\] to determine low-, moderate- and high-risk categories of EBCT scores. These cut-offs have since been used by a number of studies for reporting the validity of EBCT \[[@B9],[@B11],[@B13],[@B21],[@B23]\]. Similar cut-offs have been used in two earlier meta-analyses of studies of asymptomatic patients, including the recently published ACCF/AHA Clinical Expert Consensus Document \[[@B25],[@B26]\]. These cut-offs were determined based on a qualitative review of the literature. For example, an EBCT score of 0 was assumed to be associated with a risk of 5% or less of CAD, while a score of 400 or more was assumed to be associated with a risk of 90% or more of CAD. Based on the studies we have identified, these assumptions seem to be reasonable estimates of the risk of coronary stenosis in symptomatic patients, but not of prognostic risk in asymptomatic patients. Furthermore, we have found that even among studies of symptomatic patients there is considerable variability in these values. Nonetheless, our analyses have shown that the cut-offs proposed by Rumberger *et al*. \[[@B3]\] are clinically meaningful for classifying the aggregate patient into categories associated with a monotonically increasing risk of an adverse cardiac outcome. For asymptomatic patients this difference in risk is statistically significantly different between all categories, while in symptomatic patients the difference between moderate and high categories is only of borderline statistical significance. We found that among asymptomatic patients, negative predictive values in these same categories were very high independent of the category threshold, and thus did not help us to distinguish between categories. Among symptomatic patients, where the disease prevalence is naturally much higher, negative predictive values were lower. However, they were significantly higher in the low EBCT category compared with moderate or high categories.

We cannot comment on the utility of EBCT scores for individual risk stratification as our results were not adjusted for age, sex and other known risk factors. Therefore, while the proposed cut-offs \[[@B3]\] may be useful for making conclusions about the average patient they should not be used for individual risk stratification in light of our knowledge of the age-sex variation in coronary calcium scores \[[@B27]\]. For the average patient, our results suggest that an asymptomatic patient with a high EBCT score may benefit from extensive follow-up possibly supported by intensive medical therapy. Similar conclusions apply to asymptomatic patients classified as having a moderate EBCT score. In symptomatic patients, it appears that the average patient with a low EBCT score may have only a small chance of having coronary stenosis compared with those with high or moderate scores. Thus, they could be further evaluated with non-invasive tests possibly avoiding angiography.

Compared with earlier meta-analyses of asymptomatic subjects \[[@B26],[@B28],[@B25]\], we found four new articles \[[@B8],[@B13],[@B14],[@B12]\] and cohorts with longer follow-up for three previously included articles \[[@B10],[@B9],[@B11]\]. A previous meta-analysis \[[@B25]\] extrapolated data for individual studies in order to make them comparable when the reported EBCT cut-offs were different from the values identified to define low, moderate and high categories. Instead, we chose to use categories that were actually reported and classified them as closely as possible into low, moderate and high. Also, in contrast to this earlier meta-analysis \[[@B25]\], we chose to combine the ratios of predictive values that had not been adjusted for CAD risk factors in order to permit a larger sample size for analysis. Although our ratios of positive predictive values are slightly higher than the values from this meta-analysis \[[@B25]\], they lead to similar conclusions. Similar results were also obtained in a meta-analysis of six studies of asymptomatic patients published recently in the ACCF/AHA Clinical Expert Consensus Document \[[@B26]\]. Compared with the earlier meta-analysis of symptomatic subjects \[[@B29]\], we have identified one additional article \[[@B17]\] and added additional information in two studies \[[@B22],[@B1]\]. Unlike the previous analysis, we treated the results from one multi-centre trial as coming from a single study \[[@B15]\]. Furthermore, we divided the \'calcium positive\' scores into moderate and high categories. In our analyses of both types of studies we reported ratios comparing negative predictive values in addition to those comparing positive predictive values.

The large number of potentially relevant studies identified by our literature search reduced to 19 unique studies providing quantitative information that could be used to evaluate the utility of EBCT. Thus, despite the large number of publications about this technology, there is clearly a paucity of useful information for evaluating it. The main limitation of our study relates to the quality of the original publications and their deficiencies in following definitive standards for diagnostic publications. Combining information across the identified studies proved challenging given the lack of a standardized approach for reporting EBCT scores and the variability in recruitment methods/population across studies. Very few studies met more than 80% of the criteria identified by the STARD guidelines for measuring quality of reporting in diagnostic studies.

We were unable to separate results based on age or gender, both of which have been shown to have an important impact on the interpretation of EBCT scores. We were also unable to estimate the incremental value of EBCT beyond established risk factors. Both of these limitations were the result of the lack of access to individual-level data. For studies of asymptomatic patients we were unable to evaluate the change in risk over time in each category, as information on the time of occurrence of outcomes was not always available. Consequently, we were limited to a crude cross-sectional type analysis based only on the observed outcomes in each category at the end of each study. Also incomplete study follow-up may have also introduced bias. Finally, another possible limitation of our work may relate to our literature search where unpublished, grey literature and non-English articles were not considered. On the other hand, our search of the conventional electronic databases may be seen as thorough and systematic.

Conclusion
==========

We conclude that increasing calcium scores are associated with increasing risk of CAD among both asymptomatic and symptomatic patients. In general, it appears that asymptomatic patients with a high EBCT score may benefit from preventive interventions such as medical therapy and risk factor modification. Similar conclusions apply to asymptomatic patients classified as having a moderate EBCT score. Among symptomatic patients, those with a low EBCT score could perhaps be further evaluated with non-invasive tests possibly avoiding angiography. However, the evidence in the literature does not allow us to draw conclusions about the value of this technology for individual patients, and therefore to justify its routine use. It is especially unclear what additional value EBCT scores provide to patients in different age-sex groups. We recommend that future studies of EBCT need to: (1) use standardized cut-offs to allow for comparability; (2) adjust for the age-sex distribution of EBCT scores in classifying individuals into risk categories; and (3) use survival analysis techniques while reporting data from prospective studies.
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